Article

Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW.. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 104: 13028-13033

Department of Medicine, Division of Oncology, Stanford University School of Medicine, CA 94305, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 09/2007; 104(32):13028-33. DOI: 10.1073/pnas.0701953104
Source: PubMed

ABSTRACT Oncogene-induced senescence is an important mechanism by which normal cells are restrained from malignant transformation. Here we report that the suppression of the c-Myc (MYC) oncogene induces cellular senescence in diverse tumor types including lymphoma, osteosarcoma, and hepatocellular carcinoma. MYC inactivation was associated with prototypical markers of senescence, including acidic beta-gal staining, induction of p16INK4a, and p15INK4b expression. Moreover, MYC inactivation induced global changes in chromatin structure associated with the marked reduction of histone H4 acetylation and increased histone H3 K9 methylation. Osteosarcomas engineered to be deficient in p16INK4a or Rb exhibited impaired senescence and failed to exhibit sustained tumor regression upon MYC inactivation. Similarly, only after lymphomas were repaired for p53 expression did MYC inactivation induce robust senescence and sustained tumor regression. The pharmacologic inhibition of signaling pathways implicated in oncogene-induced senescence including ATM/ATR and MAPK did not prevent senescence associated with MYC inactivation. Our results suggest that cellular senescence programs remain latently functional, even in established tumors, and can become reactivated, serving as a critical mechanism of oncogene addiction associated with MYC inactivation.

Download full-text

Full-text

Available from: Dean Felsher, Aug 24, 2015
0 Followers
 · 
109 Views
  • Source
    • "Our study also explores the causes underlying the differential MYC requirement in cancer (von Eyss and Eilers, 2011). Prior work has emphasized MYC's role maintaining angiogenesis (Sodir et al., 2011) and its ability to restrain cellular senescence or differentiation (Lin et al., 2009; Varlakhanova et al., 2011; Wu et al., 2007). Our results indicate that the differential MYC requirement reflects, at least in part, the need to maintain the expression of the cancer-specific isoforms of pyruvate kinase (PKM2) and lactate dehydrogenase (LDH-A) (Christofk et al., 2008; Clower et al., 2010; David et al., 2010; Shim et al., 1997; Vander Heiden et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The long-term risk of malignancy associated with stem cell therapies is a significant concern in the clinical application of this exciting technology. We report a cancer-selective strategy to enhance the safety of stem cell therapies. Briefly, using a cell engineering approach, we show that aggressive cancers derived from human or murine induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are strikingly sensitive to temporary MYC blockade. On the other hand, differentiated tissues derived from human or mouse iPSCs can readily tolerate temporary MYC inactivation. In cancer cells, endogenous MYC is required to maintain the metabolic and epigenetic functions of the embryonic and cancer-specific pyruvate kinase M2 isoform (PKM2). In summary, our results implicate PKM2 in cancer's increased MYC dependence and indicate dominant MYC inhibition as a cancer-selective fail-safe for stem cell therapies.
    Cell Reports 09/2014; 8(6). DOI:10.1016/j.celrep.2014.08.039 · 8.36 Impact Factor
  • Source
    • "Inthepresentstudy,wedemonstratedusingsiRNAexperiments thatc-mycisinvolvedinhTERTtranscriptioninK-562cells.In addition,weprovidedevidencethatDAC-mediatedc-mycdown- regulationtriggerstelomere-dependentsenescencebyregulating hTERTinCML.Accordingly,c-mycdown-regulationwasreported totriggercellularsenescenceinsolidcancersandlymphoma[48]. Furthermore,genistein,apotentDNAmethyltransferaseinhibitor, wasdescribedtoabrogatehTERTtranscriptionalactivitythrough c-mycdown-regulationinprostatecancercells[49]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased proliferation rates as well as resistance to apoptosis are considered major obstacles for the treatment of patients with chronic myelogenous leukemia (CML), thus highlighting the need for novel therapeutic approaches. Since senescence has been recognized as a physiological barrier against tumorigenesis, senescence-based therapy could represent a new strategy against CML. DNA demethylating agent 5-aza-2′-deoxycytidine (DAC) was reported to induce cellular senescence but underlying mechanisms remain to be elucidated. Here, we report that exposure to DAC triggers senescence in chronic leukemia cell lines as evidenced by increased senescence-associated β-galactosidase activity and lysosomal mass, accompanied by an up-regulation of cell cycle-related genes. We provide evidence that DAC is able to decrease telomere length, to reduce telomerase activity and to decrease human telomerase reverse transcriptase (hTERT) expression through decreased binding of c-myc to the hTERT promoter. Altogether, our results reveal the role of c-myc in telomere-dependent DAC-induced senescence and therefore provide new clues for improving chronic human leukemia treatments.
  • Source
    • "mice and cell lines results in cell cycle defects and chromosomal instability (Laoukili et al., 2005; Wonsey and Follettie, 2005; Li et al., 2008). More importantly, FoxM1 À/À MEFs show increased expression of p19Arf and SA-b-Gal that are typical markers of senescent cells (Dimri et al., 1995; Wang et al., 2005; Wu et al., 2007). Low-energy laser irradiation (LELI) or low level laser irradiation (LLLI) is the use of light in the red, to near infrared, with very low intensity, that induces non-thermo-related biological events (Gavish et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cellular senescence is a growth-arrest program that limits cell proliferation. Low-power laser irradiation (LPLI) has been demonstrated to promote cell proliferation. However, whether LPLI can inhibit cellular senescence remains unknown. In the present study, to investigate the functional role of LPLI against skin aging, we used ultraviolet radiation b (UVB) to induce cell senescence. We first report that LPLI can delay UVB-induced cell senescence. The senescence-associated β-galactosidase (SA-β-Gal) activity and p21 expression, hallmarks of senescent cells, were decreased in the Forkhead box transcription factor FOXM1-dependent manner under treatment with LPLI. The effect of LPLI was further enhanced with an overexpression of FOXM1, and abolished when FOXM1 was knockdown with short hairpin RNA (shRNA). Furthermore, LPLI activated the extracellular regulated protein kinases (ERK) that was upstream of FOXM1. This led to FOXM1 phosphorylation and nuclear translocation. Nuclear translocation enhanced FOXM1 transcriptional activity and promoted its downstream target gene c-Myc expression that could inhibit p21 expression. These findings highlight the protective effects of ERK/FOXM1 pathway against UVB-induced cell senescence, suggesting a potential protecting strategy for treating skin aging by LPLI. J. Cell. Physiol. © 2013 Wiley Periodicals, Inc.
    Journal of Cellular Physiology 06/2013; 229(1). DOI:10.1002/jcp.24425 · 3.87 Impact Factor
Show more